Development of mRNA vaccines against herpes zoster.
- 1Qilu Medical University, Zibo, Shandong, China.
Abstract
Herpes zoster (HZ), caused by varicella-zoster virus (VZV), remains a substantial public health burden, particularly in aging populations, due to the risk of severe complications like postherpetic neuralgia (PHN). While existing vaccines (eg. Shingrix®) have advanced prevention efficiencies, they present notable limitations, such as high reactogenicity and complex manufacturing. mRNA vaccines represent a transformative alternative with rapid manufacturing, precise antigen design, and favorable safety. This review synthesizes the current landscape of mRNA vaccine development for HZ, focusing on the rational design of antigen constructs, innovations in lipid nanoparticle delivery systems, insights from preclinical immunogenicity studies, and the progress of leading candidates into clinical trials. In summary, this review highlights the potential of mRNA vaccines to address the limitations of current options, potentially offering a new paradigm for safer, highly efficacious, and scalable HZ prevention. Continued clinical validation is crucial to realize this potential and alleviate the global disease burden.
Related
- The effect of herpes zoster vaccines on incident dementia in England: Protocol for an OpenSAFELY regression discontinuity study
- Experimental model of VZV reactivation reveals vaccine-induced mechanisms of protection against herpes zoster
- Epitope-guided optimization improves the protective efficacy of NA-based mRNA vaccines against seasonal influenza A(H3N2) virus.
- P063 Beyond giant cell arteritis: recognising herpes zoster ophthalmicus as a vasculitis mimic
- Herpes Zoster in an Immunocompetent Child Following an Influenza-Like Illness
BibTeX
@article{li2026development,
title = {{Development of mRNA vaccines against herpes zoster.}},
author = {Dongdong Li and Jun Luo and Junwei Wang and Lining Wang and Mengyu Zhang and Jian Shen and Xiaoyu Chu and Weian Mao and Yan Zhang and Hongwu Xin},
journal = {Human vaccines \& immunotherapeutics},
year = {2026},
month = oct,
doi = {10.1080/21645515.2026.2746289},
url = {https://europepmc.org/article/MED/42867200},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Development of mRNA vaccines against herpes zoster.
AU - Dongdong Li
AU - Jun Luo
AU - Junwei Wang
AU - Lining Wang
AU - Mengyu Zhang
AU - Jian Shen
AU - Xiaoyu Chu
AU - Weian Mao
AU - Yan Zhang
AU - Hongwu Xin
PY - 2026
DA - 2026/10/13
JO - Human vaccines & immunotherapeutics
DO - 10.1080/21645515.2026.2746289
UR - https://europepmc.org/article/MED/42867200
AB - Herpes zoster (HZ), caused by varicella-zoster virus (VZV), remains a substantial public health burden, particularly in aging populations, due to the risk of severe complications like postherpetic neuralgia (PHN). While existing vaccines (eg. Shingrix®) have advanced prevention efficiencies, they present notable limitations, such as high reactogenicity and complex manufacturing. mRNA vaccines represent a transformative alternative with rapid manufacturing, precise antigen design, and favorable safety. This review synthesizes the current landscape of mRNA vaccine development for HZ, focusing on the rational design of antigen constructs, innovations in lipid nanoparticle delivery systems, insights from preclinical immunogenicity studies, and the progress of leading candidates into clinical trials. In summary, this review highlights the potential of mRNA vaccines to address the limitations of current options, potentially offering a new paradigm for safer, highly efficacious, and scalable HZ prevention. Continued clinical validation is crucial to realize this potential and alleviate the global disease burden.
SN - 2164-5515
SN - 2164-554X
ER -